Evidence map›Paper›PMID 42453880›Full record

ArticleFrontiers in oncology2026

Primary hypertrophic osteoarthropathy complicated with myelofibrosis and compound heterozygous SLCO2A1 mutations: a case report and review of literature.

Qirui Xu, Qian Li, Jin Lu, Liru Wang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qirui XuDepartment of Hematology, Fu Xing Hospital, Capital Medical University, Beijing, China.
Qian LiDepartment of Hematology, Fu Xing Hospital, Capital Medical University, Beijing, China.
Jin LuDepartment of Hematology, Fu Xing Hospital, Capital Medical University, Beijing, China.
Liru WangDepartment of Hematology, Fu Xing Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary hypertrophic osteoarthropathy (PHO) is a rare hereditary clinical syndrome characterized by digital clubbing, periostosis, and pachydermia. It is mainly caused by mutations in SLCO2A1 or HPGD, leading to impaired degradation and elevated levels of prostaglandin E2 (PGE2). In addition to the typical skeletal and skin manifestations, some patients may present with gastrointestinal or hematologic abnormalities, including anemia and myelofibrosis. This report describes a case of PHO with myelofibrosis and compound heterozygous SLCO2A1 mutations and review the literature. Case report: A 45-year-old man presented with a long history of severe fatigue and recurrent anemia accompanied by digital clubbing and skin thickening. Bone marrow biopsy revealed myelofibrosis, and imaging studies showed periostosis of the long bones. Given the anemia and gastrointestinal symptoms, differential diagnoses included Crohn's disease, intestinal tuberculosis, and other hematologic disorders associated with myelofibrosis, which were excluded by endoscopic and hematologic evaluations. Whole-exome sequencing revealed that the patient carried compound heterozygous variants in SLCO2A1 (c.940 + 1G>A and c.440G>A/p.Trp147*), confirming the diagnosis of PHO. Family investigation showed that his parents and offspring were all asymptomatic carriers with one heterozygous variant, which is consistent with autosomal recessive inheritance. Conclusion: Myelofibrosis is a rare but important complication of PHO and may be more frequent in patients with biallelic SLCO2A1 variants. Genetic testing and hematologic evaluation in PHO patients can help with early identification of related complications.

Indexed as

biallellic variantscompound heterozygous mutationmyelofibrosisprimary hypertrophic osteoarthropathySLCO2A1

Identifiers

PMID42453880
PMCPMC13364622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.